ONCS · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to Onco360 since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for ONCS yet, so no modelled value is shown. The ONCS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ONCS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for ONCS. Missing data is not estimated or replaced with scenario assumptions.
Current case
Strongest support
FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
Increased prescription volume and dispensing fees from being the national specialty dispensing partner for a newly approved oncology drug.
· Moves revenue growth rate, profitability margins from new drug distribution
What changed, by assumption
Revenue growth rate
2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
Revenue growth rate from specialty pharmacy services
2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer